Shattuck Labs Reports Q4 and 2025 Business Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy STTK?
Source: NASDAQ.COM
- Improved Financial Performance: Shattuck Labs reported a net loss of $12.6 million ($0.12 per share) for Q4 2025, a significant improvement from the $18.7 million loss a year ago, and it surpassed the analyst estimate of $0.13, indicating effective cost management.
- Reduced R&D Spending: The company managed to cut its operating loss to $13.4 million from $19.6 million by reducing research and development expenses, reflecting a more cautious approach to resource allocation that enhances future financial flexibility.
- Progress on SL-325: Shattuck's lead developmental drug, SL-325, has completed enrollment in all six single-ascending dose cohorts, with full enrollment in the final multiple-ascending dose trial expected in Q2, and important data is anticipated to be released during this period, potentially laying the groundwork for future market performance.
- Strong Cash Position: With over $78 million in cash and short-term investments, the company is well-positioned to fund its operations into 2029, providing a solid financial foundation for Shattuck's ongoing development in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STTK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STTK
Wall Street analysts forecast STTK stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.960
Low
4.00
Averages
8.33
High
15.00
Current: 5.960
Low
4.00
Averages
8.33
High
15.00
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Shattuck Labs Reports Strong Earnings, Shares Surge 53%
- Strong Earnings Report: Shattuck Labs reported its Q4 2025 results, with operational losses decreasing from $19.6 million in 2024 to $13.4 million, demonstrating effective cost control in R&D, and a headline net loss of $0.12 per share, surpassing the analyst estimate of $0.13, indicating improved financial health.
- R&D Progress: The company's lead drug SL-325 has completed enrollment in all six single-ascending dose cohorts, with full enrollment in the final multiple-ascending dose trial expected in Q2, and management plans to release significant data during this quarter, which could positively impact future market performance.
- Sufficient Funding for Development: With over $78 million in cash and short-term investments, Shattuck Labs is well-positioned to fund its operations through 2029, providing ample financial backing for R&D and market expansion, thereby boosting investor confidence.
- Promising Market Outlook: As SL-325 is a versatile medication for multiple indications, the positive advancements in its development have generated investor enthusiasm, and combined with the company's strong financial performance, it positions Shattuck as a biotech investment worth watching.
See More
Shattuck Labs Reports Q4 and 2025 Business Update
- Improved Financial Performance: Shattuck Labs reported a net loss of $12.6 million ($0.12 per share) for Q4 2025, a significant improvement from the $18.7 million loss a year ago, and it surpassed the analyst estimate of $0.13, indicating effective cost management.
- Reduced R&D Spending: The company managed to cut its operating loss to $13.4 million from $19.6 million by reducing research and development expenses, reflecting a more cautious approach to resource allocation that enhances future financial flexibility.
- Progress on SL-325: Shattuck's lead developmental drug, SL-325, has completed enrollment in all six single-ascending dose cohorts, with full enrollment in the final multiple-ascending dose trial expected in Q2, and important data is anticipated to be released during this period, potentially laying the groundwork for future market performance.
- Strong Cash Position: With over $78 million in cash and short-term investments, the company is well-positioned to fund its operations into 2029, providing a solid financial foundation for Shattuck's ongoing development in the biotech sector.
See More
Shattuck Labs Reports 2025 Financial Results and Pipeline Progress
- Narrowing Financial Losses: Shattuck Labs reported a net loss of $12.6 million in Q4 2025, translating to $0.12 per share, a significant improvement from the $18.7 million loss and $0.37 per share in Q4 2024, indicating enhanced financial health that may boost investor confidence.
- Annual Loss Reduction: For the full year 2025, the company narrowed its net loss to $48.8 million, or $0.70 per share, down from $75.4 million and $1.49 per share in 2024, reflecting progress in cost management and operational efficiency.
- Clinical Trial Advancements: Shattuck's lead candidate SL-325 is currently in a Phase 1 clinical trial, with all single-ascending dose (SAD) cohorts enrolled, and the final multiple-ascending dose (MAD) cohort expected to complete by Q2 2026, laying the groundwork for subsequent Phase 2 trials.
- Strong Cash Position: The company ended 2025 with $78.1 million in cash and equivalents, and a subsequent capital raise in early 2026 is projected to extend its cash runway into 2029, enhancing financial flexibility for R&D and market expansion.
See More
Shattuck Labs Q4 Earnings Beat Expectations
- Earnings Highlights: Shattuck Labs reported a Q4 GAAP EPS of -$0.12, beating market expectations by $0.01, indicating positive signals in the company's recovery of profitability.
- Cash Position Improvement: As of December 31, 2025, cash and cash equivalents along with short-term investments totaled approximately $78.1 million, up from $73.0 million on December 31, 2024, reflecting improved liquidity that supports future investments.
- Market Rating Upgrade: Piper Sandler upgraded Shattuck Labs to an “Overweight” rating, reflecting market optimism regarding upcoming catalysts that could drive stock price increases.
- Strategic Competitive Adjustments: Shattuck Labs maintains a “Hold” on its oncology exit and competitive TL1A/DR3 pathway pivot, demonstrating a cautious approach in the face of market competition, aiming to optimize resource allocation for long-term growth.
See More
Shattuck Labs Reports Reduced Losses in Q4
- Financial Performance Improvement: Shattuck Labs reported a fourth-quarter loss of $12.593 million, a decrease from last year's loss of $18.679 million, indicating initial success in cost control measures.
- Earnings Per Share Recovery: The loss per share improved from $0.37 last year to $0.12, suggesting some progress in profitability, although the company remains in a loss position.
- Year-over-Year Comparison: The reduction in losses by 32.5% compared to last year reflects improvements in operational efficiency and financial management, potentially providing confidence to future investors.
- Market Reaction Expectations: Despite still being in a loss position, the improvement in financial data may attract more investor attention, especially as the company seeks further financing and business expansion opportunities.
See More
Shattuck Labs Reports Progress on SL-325 Clinical Trials
- Clinical Trial Progress: Shattuck Labs' SL-325 is currently in Phase 1 clinical trials, with data expected in Q2 2026, marking the first clinical data for a DR3 blocking antibody, potentially paving the way for new treatments for inflammatory diseases.
- Phase 2 Trial Plans: The company anticipates initiating a Phase 2 clinical trial for SL-325 in Crohn's disease in Q3 2026, which will further validate its potential in treating immune-mediated diseases and could enhance the company's market performance.
- Improved Financial Position: As of December 31, 2025, Shattuck reported approximately $78.1 million in cash and cash equivalents, an increase from $73.0 million in 2024, indicating stability in financing and operations.
- Reduced R&D Expenses: R&D expenses for Q4 2025 were $9.1 million, significantly down from $15.4 million in Q4 2024, reflecting the company's strategic focus on optimizing resource allocation and concentrating on core projects.
See More
Shattuck Labs Reports Strong Earnings, Shares Surge 53%
- Strong Earnings Report: Shattuck Labs reported its Q4 2025 results, with operational losses decreasing from $19.6 million in 2024 to $13.4 million, demonstrating effective cost control in R&D, and a headline net loss of $0.12 per share, surpassing the analyst estimate of $0.13, indicating improved financial health.
- R&D Progress: The company's lead drug SL-325 has completed enrollment in all six single-ascending dose cohorts, with full enrollment in the final multiple-ascending dose trial expected in Q2, and management plans to release significant data during this quarter, which could positively impact future market performance.
- Sufficient Funding for Development: With over $78 million in cash and short-term investments, Shattuck Labs is well-positioned to fund its operations through 2029, providing ample financial backing for R&D and market expansion, thereby boosting investor confidence.
- Promising Market Outlook: As SL-325 is a versatile medication for multiple indications, the positive advancements in its development have generated investor enthusiasm, and combined with the company's strong financial performance, it positions Shattuck as a biotech investment worth watching.
See More
Shattuck Labs Reports Q4 and 2025 Business Update
- Improved Financial Performance: Shattuck Labs reported a net loss of $12.6 million ($0.12 per share) for Q4 2025, a significant improvement from the $18.7 million loss a year ago, and it surpassed the analyst estimate of $0.13, indicating effective cost management.
- Reduced R&D Spending: The company managed to cut its operating loss to $13.4 million from $19.6 million by reducing research and development expenses, reflecting a more cautious approach to resource allocation that enhances future financial flexibility.
- Progress on SL-325: Shattuck's lead developmental drug, SL-325, has completed enrollment in all six single-ascending dose cohorts, with full enrollment in the final multiple-ascending dose trial expected in Q2, and important data is anticipated to be released during this period, potentially laying the groundwork for future market performance.
- Strong Cash Position: With over $78 million in cash and short-term investments, the company is well-positioned to fund its operations into 2029, providing a solid financial foundation for Shattuck's ongoing development in the biotech sector.
See More
Shattuck Labs Reports 2025 Financial Results and Pipeline Progress
- Narrowing Financial Losses: Shattuck Labs reported a net loss of $12.6 million in Q4 2025, translating to $0.12 per share, a significant improvement from the $18.7 million loss and $0.37 per share in Q4 2024, indicating enhanced financial health that may boost investor confidence.
- Annual Loss Reduction: For the full year 2025, the company narrowed its net loss to $48.8 million, or $0.70 per share, down from $75.4 million and $1.49 per share in 2024, reflecting progress in cost management and operational efficiency.
- Clinical Trial Advancements: Shattuck's lead candidate SL-325 is currently in a Phase 1 clinical trial, with all single-ascending dose (SAD) cohorts enrolled, and the final multiple-ascending dose (MAD) cohort expected to complete by Q2 2026, laying the groundwork for subsequent Phase 2 trials.
- Strong Cash Position: The company ended 2025 with $78.1 million in cash and equivalents, and a subsequent capital raise in early 2026 is projected to extend its cash runway into 2029, enhancing financial flexibility for R&D and market expansion.
See More
Shattuck Labs Q4 Earnings Beat Expectations
- Earnings Highlights: Shattuck Labs reported a Q4 GAAP EPS of -$0.12, beating market expectations by $0.01, indicating positive signals in the company's recovery of profitability.
- Cash Position Improvement: As of December 31, 2025, cash and cash equivalents along with short-term investments totaled approximately $78.1 million, up from $73.0 million on December 31, 2024, reflecting improved liquidity that supports future investments.
- Market Rating Upgrade: Piper Sandler upgraded Shattuck Labs to an “Overweight” rating, reflecting market optimism regarding upcoming catalysts that could drive stock price increases.
- Strategic Competitive Adjustments: Shattuck Labs maintains a “Hold” on its oncology exit and competitive TL1A/DR3 pathway pivot, demonstrating a cautious approach in the face of market competition, aiming to optimize resource allocation for long-term growth.
See More
Shattuck Labs Reports Reduced Losses in Q4
- Financial Performance Improvement: Shattuck Labs reported a fourth-quarter loss of $12.593 million, a decrease from last year's loss of $18.679 million, indicating initial success in cost control measures.
- Earnings Per Share Recovery: The loss per share improved from $0.37 last year to $0.12, suggesting some progress in profitability, although the company remains in a loss position.
- Year-over-Year Comparison: The reduction in losses by 32.5% compared to last year reflects improvements in operational efficiency and financial management, potentially providing confidence to future investors.
- Market Reaction Expectations: Despite still being in a loss position, the improvement in financial data may attract more investor attention, especially as the company seeks further financing and business expansion opportunities.
See More
Shattuck Labs Reports Progress on SL-325 Clinical Trials
- Clinical Trial Progress: Shattuck Labs' SL-325 is currently in Phase 1 clinical trials, with data expected in Q2 2026, marking the first clinical data for a DR3 blocking antibody, potentially paving the way for new treatments for inflammatory diseases.
- Phase 2 Trial Plans: The company anticipates initiating a Phase 2 clinical trial for SL-325 in Crohn's disease in Q3 2026, which will further validate its potential in treating immune-mediated diseases and could enhance the company's market performance.
- Improved Financial Position: As of December 31, 2025, Shattuck reported approximately $78.1 million in cash and cash equivalents, an increase from $73.0 million in 2024, indicating stability in financing and operations.
- Reduced R&D Expenses: R&D expenses for Q4 2025 were $9.1 million, significantly down from $15.4 million in Q4 2024, reflecting the company's strategic focus on optimizing resource allocation and concentrating on core projects.
See More
